Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.
Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company pioneering novel therapies for multidrug-resistant bacterial infections and rare diseases. This page serves as the definitive source for verified news and official updates on SPRO's research advancements, regulatory milestones, and strategic initiatives.
Investors and healthcare professionals will find timely updates on key programs including tebipenem HBr (oral carbapenem antibiotic), SPR206 (IV polymyxin), and other pipeline developments. The curated news collection covers clinical trial results, FDA communications, partnership announcements, and financial disclosures.
All content is rigorously verified to ensure accuracy and relevance for stakeholders monitoring antibiotic innovation. Bookmark this page for direct access to SPRO's latest developments in addressing critical unmet medical needs through advanced therapeutic candidates.
Spero Therapeutics (Nasdaq: SPRO) reported its Q1 2024 financial results and provided a business update. The company continues advancing its clinical pipeline, with key trials underway. Topline data for SPR720, aimed at treating NTM-PD, is expected in 2H 2024. The Phase 3 trial for tebipenem HBr in cUTI is ongoing, with enrollment completion targeted for 2H 2025. SPR206 received FDA Fast Track designation for HABP/VABP treatment.
Spero reported a net loss of $12.7 million for Q1 2024, a slight improvement from $13.3 million a year ago. Revenue surged to $9.3 million, primarily due to increased collaboration and grant revenues. R&D expenses rose to $17.3 million, reflecting heightened clinical activity. G&A expenses decreased to $5.9 million. The company's cash balance stands at $82.3 million, up from $76.3 million at year-end 2023, bolstered by a $23.8 million milestone payment from GSK. Spero's financial runway is expected to extend into late 2025.
Spero Therapeutics, Inc. (Nasdaq: SPRO) will report its first quarter 2024 financial results and business update on May 15, 2024. The company focuses on developing treatments for rare diseases and MDR bacterial infections.
Spero Therapeutics, Inc. announced the approval of 10,833 restricted stock unit awards to a new employee under the 2019 Inducement Plan. The RSUs will vest in four equal annual installments beginning on May 1, 2025, subject to the employee's continued employment.
FAQ
What is the current stock price of Spero Therapeuti (SPRO)?
What is the market cap of Spero Therapeuti (SPRO)?
